OncoMed Pharmaceuticals, Inc. Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent In The U.S.

OncoMed Pharmaceuticals, Inc. , a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, has been granted a new patent in the United States for OncoMed's anti-DLL4/anti-VEGF bispecific antibody and use of the bispecific antibody in the treatment of cancer. The new patent includes both composition-of-matter and method of treatment claims for the antibody.

http://ift.tt/10jJXRK